Swedish Orphan Biovitrum

What Swedish Orphan Biovitrum does

Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company headquartered in Stockholm, Sweden, that develops and commercializes specialty therapies exclusively for rare diseases. The company was founded in 1988, is listed on Nasdaq Stockholm (STO:SOBI), and employs approximately 1,900 people across Europe, North America, the Middle East, Asia, and North Africa. Sobi operates through three business units: Haematology (haemophilia A, immune thrombocytopenia, paroxysmal nocturnal haemoglobinuria, diffuse large B-cell lymphoma), Immunology (familial Mediterranean fever, CAPS, HLH, Still's disease), and Specialty Care (FCS, HT-1, hATTR). The portfolio includes branded biologics such as Altuvoct/ALTUVIIIO (efanesoctocog alfa for haemophilia A), Gamifant (emapalumab for HLH), Kineret (anakinra), EMPAVELI/Aspaveli (pegcetacoplan for complement-mediated diseases), Doptelet (avatrombopag for ITP), and Orfadin (nitisinone for HT-1). The product set is heavily weighted to biologics, with underlying capabilities in protein biochemistry and biologics manufacturing development.

Sobi monetizes through specialty pharmaceutical product sales, pricing medicines via government reimbursement schemes, hospital tenders, and insurance coverage across more than 30 countries. The go-to-market combines a specialized sales force targeting hematologists, immunologists, nephrologists, and metabolic disease specialists with medical-conference presence, scientific publications, and key-opinion-leader engagement. Distribution flows through hospital and specialty pharmacy channels; strategic partnerships with Sanofi (ALTUVIIIO in the U.S., Sobi ex-U.S. rights) and Apellis/Biogen (EMPAVELI in the U.S., Sobi ex-U.S. rights) extend commercial reach. FY2025 revenue was SEK 28,238 million (15% growth at constant exchange rates) with a 40% adjusted EBITA margin, and the company treated over 53,000 patients in 2025.

Sobi combines organic pipeline development with inorganic growth: the 2023 acquisition of CTI BioPharma added a commercial-stage myelofibrosis asset, the February 2026 acquisition of Arthrosi Therapeutics (up to USD 1.5B) added a Phase 3 gout candidate, and capital has been raised via a 2023 rights issue (SEK 6,024M) and a 2024 inaugural senior bond (SEK 3B). The company has stated a goal of launching six new products by 2028 to double in size, with active regulatory filings across the EMA, FDA, and Health Canada.

Name

Swedish Orphan Biovitrum

Legal name

Swedish Orphan Biovitrum AB (publ)

Website

https://sobi.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sobi is a global biopharmaceutical company headquartered in Stockholm, Sweden, that develops and commercializes therapies for rare diseases across haematology, immunology, and specialty care, serving over 53,000 patients in more than 30 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Solna

HQ country

Sweden

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Specialty pharmaceutical product sales: Sobi generates revenue primarily through the sale of prescription biopharmaceutical medicines for rare diseases. Revenue is driven by both haematology products (Altuvoct, Doptelet) and immunology products (Gamifant, Kineret). The company reports revenue across two main segments: haematology and immunology, with a strategic portfolio representing approximately 65% of Q4 revenues.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Sobi is a global biopharmaceutical company that develops, manufactures, and commercialises therapies for rare diseases across haematology, immunology, and specialty care. Its portfolio includes biologics and small molecules such as Altuvoct, Doptelet, EMPAVELI/Aspaveli, Gamifant, Kineret, Tryngolza, Orfadin, and the late-stage asset pozdeutinurad (AR882), which it sells to hospitals, specialty treatment centres, and specialty pharmacies worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Liberate Life: Patient support program and brand for haemophilia patients, featuring patient stories, joint health programs, and lifestyle resources.

Products and services

• Altuvoct (efanesoctocog alfa) Extended half-life recombinant factor VIII fusion therapy for the treatment and prevention of bleeding episodes in patients with haemophilia A; sold to hospitals, haemophilia treatment centres, and specialty prescribers.

Quantifiable outcome

• Revenue growth of 15% at constant exchange rates to SEK 28 billion in 2025
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• SanoficoreStrategic or Co-development PartnerSobi collaborates with Sanofi on the development and commercialisation of ALTUVOCT (efanesoctocog alfa). Sobi holds exclusive rights in Europe, North Africa, Russia, and most Middle Eastern markets. Sanofi commercializes the product as ALTUVIIIO in the United States. This partnership enables Sobi to leverage Sanofi's U.S. commercial infrastructure while maintaining direct commercialization in its home territories.
• Apellis Pharmaceuticals (now part of Biogen)coreStrategic or Co-development PartnerSobi holds exclusive ex-U.S. commercialization rights for pegcetacoplan (EMPAVELI/Aspaveli) while Apellis holds U.S. rights. The collaboration includes the VALIANT Phase 3 study and long-term extension VALE study for C3G and primary IC-MPGN. Sobi also secured up to $300 million through a royalty agreement with Apellis.
• Hellenic Institute for the Study of Sepsis (HISS)minorStrategic or Co-development PartnerThe EMBRACE Phase 2a study evaluating emapalumab (Gamifant) in interferon-gamma-driven sepsis was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) in collaboration with Sobi. The study enrolled 75 patients across 24 sites in Greece and supported regulatory discussions for a potential new indication.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vertex Pharmaceuticals: Specialty biopharmaceutical company focused on rare diseases (cystic fibrosis, sickle cell, pain), with a similar model of addressing high-unmet-need genetic and serious diseases through differentiated therapies and global specialty commercialization.
• BioMarin Pharmaceutical: Pure-play rare disease biopharma developing and commercializing therapies for genetic and ultra-rare conditions. Direct competitor in the rare disease specialty model with similar revenue scale and focus on orphan drug regulatory pathways.
• Alexion (AstraZeneca Rare Disease): Once an independent rare disease specialist (now within AstraZeneca), Alexion pioneered the rare disease commercial model with Soliris/Ultomiris — overlapping with Sobi in haematology (PNH, aHUS) and competing in the same specialist prescriber channels.
• Alnylam Pharmaceuticals: RNAi therapeutics leader focused on rare genetic diseases, with a comparable model of premium-priced orphan biologics, specialist sales channels, and global partnerships (similar to Sobi's relationship with Apellis).
• Apellis Pharmaceuticals: Sobi's pegcetacoplan partner and a directly comparable rare disease biopharma with overlapping haematology/nephrology indications (PNH, C3G), similar revenue scale, and shared commercialization model.
• Recordati: European specialty pharma group with a dedicated rare disease franchise, similar commercial reach across Europe and emerging markets, and comparable revenue/profitability profile to Sobi.
• Ipsen: European specialty biopharma with strong rare disease and specialty care franchises, overlapping target physician audiences (specialists/hospital channels), and similar geographic diversification strategy.
• Ionis Pharmaceuticals: RNA-targeted therapeutics developer whose olezarsen (Tryngolza) is being commercialized with Sobi for rare lipid disorders. Operates the same model of licensing rare disease assets to commercial partners.

Emerging players

• Genmab: Danish biotech with antibody-based therapies for cancer and rare diseases; comparable European specialty biotech profile, though more oncology-weighted than Sobi.

Broad incumbents

• Takeda Pharmaceutical: Large global biopharma with a substantial rare disease and haematology franchise (post-Shire), overlapping Sobi in haemophilia and rare immunology but at much greater scale and broader portfolio scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/Sobi-Pharma
• LinkedInlinkedin.com/company/sobi

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swedish Orphan Biovitrum